Ticker League

Revolution Medicines (RVMD) Free Cash Flow Bridge

Pinpoint what moved Revolution Medicines's free cash flow from TTM through Q1 2025 to TTM through Q1 2026 — operating cash flow shifts and capex changes, each driver sized in dollars.

TTM

FCF YoY

-78.11%

OCF YoY

-78.83%

Capex YoY

+37.04%

FCF Conversion Δ

Free cash flow bridge for Revolution Medicines (RVMD) — TTM through Q1 2026 vs TTM through Q1 2025

Δ Free cash flow: −$470.01M

FCF bridge breakdown for Revolution Medicines (RVMD) — TTM through Q1 2026 vs TTM through Q1 2025

  • Prior Free Cash Flow−$601.72M
  • Operating Cash Flow−$466.16M
  • Capital Expenditure−$3.85M
  • Free Cash Outflow−$1.07B
Identity check: drivers reconcile to ΔNI within $0.00
Want to see how cash flow is built up?Cash Flow Waterfall

Frequently asked questions

Data & methodology

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation